NIH funds Expanded Access Program for NUZ-001 in ALS
Filed with ASX · · 3 pages · English
Neurizon Therapeutics Limited on 6ix
Earlier from Neurizon Therapeutics
- Neurizon Appoints Chief Executive Officer
- Appendix 4E and 2026 Annual Report
- Neurizon Enters Strategic R&D Financing Facility
- HEALEY ALS Platform Trial Regimen I enrolment completed - Topline results for NUZ-001 accelerated to Q2 CY2027
- HEALEY Enrolment Complete - Topline Accelerated to Q2 CY27
Later from Neurizon Therapeutics
- Neurizon Announces Partial Redemption of Convertible Notes
- FDA Type C Feedback, HEALEY trial potentially registrational
- Appendix 4C & Quarterly Update
- Trading Halt
- Firm commitments to raise A$4.3m and announcement of SPP
Follow Neurizon Therapeutics into a list and get an email when it puts out news.
Follow Neurizon Therapeutics